Supply Issue - lanreotide inj 60 mg per 0.5 ml, 0.5 ml syringe (Mytolac)

New listing:

We are writing to inform you of a brand change for lanreotide inj 60 mg per 0.5 ml, 0.5 ml syringe (Mytolac). Due to a supply issue with the Mytolac brand we have an alternate brand funded and available.

Key messages:

• lanreotide inj 60 mg per 0.5 ml, 0.5 ml syringe (Mytolac) brand is in short supply due to manufacturing delays.

• Alternative Mytolac Section 29 product was listed (funded) 1 July 2025.

• Mytolac S29 - The outer box is in English with Mytolac as the brand. Inside the box the foil and syringe have Italian text and the brand name Myrelez, together with the generic name. A NZ datasheet is included.

• A letter from the supplier BNM detailing the alternative is attached to this email.

• In this letter BNM says - The Myrelez branded product is produced by the same manufacturer at the same manufacturing site and is identical in every way apart from the Italian labelling.

• See images Mytolac on Pharmac website.

• The supplier expects to have the Medsafe approved Mytolac 60 mg per 0.5 ml, 0.5 ml syringe available again in March 2026.

• We appreciate your support in managing this situation and providing reassurance to affected patients. This approach will enable patients to continue to access treatment. Please ensure those who are self-administering this injection are aware of this change.

Please share this information:

Please share this information with your colleagues and within your networks.

Questions:

If you have any queries, please reply to this email

Ngā mihi

Dr David Hughes

Chief Medical Officer | Director Advice & Assessment

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

DDI: +64 21 962 317 | P: +64 4 460 4990 |  www.pharmac.govt.nz